throbber
[CANCER RESEARCH 64, 252–261, January 1, 2004]
`
`Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin
`Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal
`Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells
`
`Anne Boulay,1 Sabine Zumstein-Mecker,1 Christine Stephan,1 Iwan Beuvink,2 Frederic Zilbermann,2 Roland Haller,1
`Sonja Tobler,1 Christoph Heusser,1 Terence O’Reilly,1 Barbara Stolz,1 Andreas Marti,1 George Thomas,2 and
`Heidi A. Lane1
`1Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland, and 2Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
`
`ABSTRACT
`
`The orally bioavailable rapamycin derivative RAD001 (everolimus)
`targets the mammalian target of rapamycin pathway and possesses potent
`immunosuppressive and anticancer activities. Here, the antitumor activity
`of RAD001 was evaluated in the CA20948 syngeneic rat pancreatic tumor
`model. RAD001 demonstrated dose-dependent antitumor activity with
`daily and weekly administration schedules; statistically significant antitu-
`mor effects were observed with 2.5 and 0.5 mg/kg RAD001 administered
`daily [treated tumor versus control tumor size (T/C), 23% and 23–30%,
`respectively], with 3–5 mg/kg RAD001 administered once weekly (T/C,
`14 –36%), or with 5 mg/kg RAD001 administered twice weekly (T/C,
`36%). These schedules were well tolerated and exhibited antitumor po-
`tency similar to that of the cytotoxic agent 5-fluorouracil (T/C, 23%).
`Moreover, the efficacy of intermittent treatment schedules suggests a
`therapeutic window allowing differentiation of antitumor activity from
`the immunosuppressive properties of this agent. Detailed biochemical
`profiling of mammalian target of rapamycin signaling in tumors, skin, and
`peripheral blood mononuclear cells (PBMCs), after a single administra-
`tion of 5 mg/kg RAD001,
`indicated that RAD001 treatment blocked
`phosphorylation of the translational repressor eukaryotic initiation factor
`4E-binding protein 1 and inactivated the translational activator ribosomal
`protein S6 kinase 1 (S6K1). The efficacy of intermittent treatment sched-
`ules was associated with prolonged inactivation of S6K1 in tumors and
`surrogate tissues (>72 h). Furthermore, detailed analysis of the dose
`dependency of weekly treatment schedules demonstrated a correlation
`between antitumor efficacy and prolonged effects (>7 days) on PBMC-
`derived S6K1 activity. Analysis of human PBMCs revealed that S6K1 also
`underwent a concentration-dependent inactivation after RAD001 treat-
`ment ex vivo (>95% inactivation with 20 nM RAD001). In contrast,
`human PBMC-derived eukaryotic initiation factor 4E-binding protein 1
`was present predominantly in the hypophosphorylated form and was
`unaffected by RAD001 treatment. Taken together, these results demon-
`strate a correlation between the antitumor efficacy of
`intermittent
`RAD001 treatment schedules and prolonged S6K1 inactivation in PBMCs
`and suggest that long-term monitoring of PBMC-derived S6K1 activity
`levels could be used for assessing RAD001 treatment schedules in cancer
`patients.
`
`INTRODUCTION
`
`RAD001 (everolimus), an orally bioavailable derivative of rapamy-
`cin, is a macrolide antifungal antibiotic that demonstrates potent
`antiproliferative effects against a variety of mammalian cell types.
`Specifically, RAD001 inhibits cytokine-driven lymphocyte prolifera-
`tion (1), as well as the proliferation of human tumor-derived cells
`
`Received 12/18/02; revised 9/10/03; accepted 10/30/03.
`Grant support: Iwan Beuvink, Frederic Zilbermann, and George Thomas were
`supported by Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Insti-
`tute for Biomedical Research.
`The costs of publication of this article were defrayed in part by the payment of page
`charges. This article must therefore be hereby marked advertisement in accordance with
`18 U.S.C. Section 1734 solely to indicate this fact.
`Note: Anne Boulay and Sabine Zumstein-Mecker contributed equally to this work.
`Requests for reprints: Heidi A. Lane, Novartis Institutes for BioMedical Research
`Basel, Oncology, Novartis Pharma AG, WKL-125.13.17, CH-4002 Basel, Switzerland.
`Phone: 41-61-696-5438; Fax: 41-61-696-3835; E-mail: heidi.lane@pharma.novartis.com.
`252
`
`grown either in culture or as tumors in animal models (2, 3). As a
`result of these properties, RAD001 is being clinically developed both
`as an immunosuppressant for prevention of allograft rejection (Certi-
`can; Ref. 1) and as a novel therapeutic in the fight against human
`cancer (2– 4).
`RAD001, like rapamycin, binds with high affinity to a ubiquitous
`intracellular receptor, the immunophilin FKBP12. This complex spe-
`cifically interacts with the mammalian target of rapamycin (mTOR)
`protein kinase;
`inhibiting downstream signaling events (5). The
`mTOR kinase is a member of the phosphoinositide kinase-related
`kinase family, which consists of high molecular weight serine/threo-
`nine kinases involved in cell cycle checkpoint control (6). Several
`lines of evidence suggest that mTOR acts as a sensor for stress (7) and
`the availability of amino acids (8 –10) or intracellular ATP (11). In the
`presence of mitogens and sufficient nutrients, mTOR relays a signal to
`translational regulators, specifically enhancing the translation of mR-
`NAs encoding proteins essential for cell growth (12) and progression
`through the G1 to S transition (13, 14). Consistent with targeting the
`mTOR pathway, treatment of mammalian cells with rapamycin has
`been shown to inhibit these signaling events, mimicking a starvation
`phenotype (15) and leading to growth retardation and accumulation of
`cells in G1 phase (16). The mechanism of growth stimulus and
`nutrient level integration by mTOR is, as yet, not fully understood.
`However, an increasing body of evidence suggests the involvement of
`the phosphatidylinositol 3⬘-kinase/Akt/TSC/Rheb pathway (12, 17–
`23). Indeed, it has been suggested that, in tumor cells, the activation
`status of the Akt pathway may be indicative of responsiveness to
`rapamycin or its derivatives (24 –27).
`mTOR is part of a multisubunit complex that contains the regula-
`tory proteins raptor (28, 29) and G␤L (30). The mTOR complex
`signals to at least two downstream effectors, the translational repres-
`sor protein eukaryotic initiation factor 4E (eIF-4E)-binding protein 1
`(4E-BP1) and ribosomal protein S6 kinase 1 (S6K1). These share an
`evolutionary conserved amino acid motif, the TOS motif, that func-
`tions as a docking site for raptor (31–33). Binding of 4E-BP1 to the
`translational activator eIF-4E is modulated by mTOR-dependent
`phosphorylation of specific serine and threonine residues (5). Ser37
`and Ser46 are constitutively phosphorylated, acting as priming sites
`for the mitogen-induced, rapamycin-sensitive phosphorylation of
`Thr70 and Ser65 (34). After a final phosphorylation event at Ser65,
`4E-BP1 dissociates from eIF-4E (35), thereby allowing the reconsti-
`tution of a translationally competent initiation factor complex (eIF-4F;
`Ref. 5). eIF-4F activation results in the translation of a subset of
`capped mRNA containing highly structured 5⬘-untranslated regions
`and encoding proteins involved in G1- to S-phase progression (13,
`14). Mitogen-induced activation of the S6K1 is also dependent on
`mTOR function and has been implicated in the translational regulation
`of mRNAs possessing a 5⬘-terminal oligopyrimidine tract (36 –38).
`5⬘-Terminal oligopyrimidine tract mRNAs are characterized by a
`stretch of 4 –14 pyrimidines located at their extreme 5⬘ terminus and
`typically encode ribosomal proteins as well as components of the
`
`Roxane Labs., Inc.
`Exhibit 1025
`Page 001
`
`

`
`RAPAMYCIN DERIVATIVE RAD001: EFFICACY AND BIOMARKERS
`
`translational machinery. Activation of S6K1 itself is also tightly
`regulated by hierarchical phosphorylation events, which are depend-
`ent on the activation of various signal transduction pathways and
`culminate in the phosphorylation of the rapamycin-sensitive site
`Thr389, an event closely paralleling kinase activation (12, 39). Im-
`munopurified mTOR has been shown to autophosphorylate on
`Ser2481 (40) and to phosphorylate Ser37, Ser46, and Ser65 on 4E-
`BP1 in vitro (11, 34, 41, 42). However, some of these events have
`been demonstrated to be resistant to antiproliferative concentrations of
`rapamycin (40 – 42). It is therefore unclear what role mTOR kinase
`activity plays per se in rapamycin-sensitive signaling events.
`Because mTOR couples nutrient/growth factor availability to cell
`growth and proliferation in a variety of cell types, there is a potential
`for developing rapamycin derivatives such as RAD001 as novel
`inhibitors of the deregulated cell growth characteristic of human
`cancers. Consistent with this, RAD001 inhibits the proliferation of a
`wide variety of human solid tumor cell lines both in vitro in cell
`culture and in vivo in animal xenograft models (2, 3, 27, 43, 44).
`Furthermore, antiproliferative effects of RAD001 in posttransplant
`lymphoproliferative disorder-like B cell lines have been observed in
`vitro and in vivo (45, 46). In the present study, we have demonstrated
`that RAD001 displays significant antitumor activity in the syngeneic
`CA20948 rat pancreatic tumor model. Equivalent activity was ob-
`served with daily and intermittent treatment schedules, suggesting the
`possibility of a therapeutic window allowing differentiation of anti-
`tumor activity from the immunosuppressive properties of this agent.
`Detailed biochemical analysis of the mTOR effectors 4E-BP1 and
`S6K1 in tumor, skin, and peripheral blood mononuclear cell (PBMC)
`extracts obtained from RAD001-treated rats suggests that modulation
`of 4E-BP1 activity and significant inactivation of S6K1 are associated
`with antitumor activity. Furthermore, the efficacy observed using
`intermittent treatment schedules is paralleled by long-term down-
`regulation of S6K1 activity in all three tissues. We also provide
`evidence that the duration of S6K1 inactivation in PBMCs correlates
`with the dose-dependent suppression of tumor growth observed with
`weekly regimens. Moreover, unlike 4E-BP1 phosphorylation, S6K1
`activity can be reproducibly measured in human PBMCs and repre-
`sents a potentially valuable pharmacodynamic biomarker by which to
`monitor RAD001 treatment schedules in cancer patients.
`
`MATERIALS AND METHODS
`
`Drug Preparation. RAD001 (everolimus) is a derivative of rapamycin
`[40-O-(2-hydroxyethyl)-rapamycin; Ref. 47]. For animal studies, RAD001 was
`formulated at 2% (w/v) in a microemulsion vehicle, which was diluted to the
`appropriate concentration in 5% (w/v) glucose solution just before adminis-
`tration by gavage. For in vitro and ex vivo analyses, RAD001 was prepared in
`DMSO before addition to cell culture or human volunteer blood samples.
`Antitumor Efficacy Studies and Statistical Analyses. Male Lewis rats
`were purchased from Iffa Credo (L’Abresque, France) and allowed food and
`water ad libitum. A suspension of CA20948 tumor cells (obtained from donor
`rats because this line is nonculturable in vitro) in Ham’s F-12 medium
`supplemented with 10% FCS, 0.1 g/100 ml NaHCO3, 1% penicillin, and 1%
`fungizone was injected s.c. into the left flank of rats. Treatment of randomized
`rats started when the tumors reached about 100 mm3. RAD001 was adminis-
`tered p.o. daily at 0.5 or 2.5 mg/kg (⫻6/week), twice weekly at 5 mg/kg, or
`weekly at 0.5, 1, 2, 3, or 5 mg/kg. A volume of vehicle equivalent to the
`highest dose of RAD001 administered in the experiment was used as a
`negative control. As a positive control, the cytotoxic agent 5-fluorouracil
`(5-FU; ICN Pharmaceuticals Inc., Costa Mesa, CA) was administered at a near
`maximum tolerated dose (15 mg/kg, i.v., 4⫻/week, 2 days treatment/2 days
`rest), which gives maximal antitumor effect. Tumors were measured every day
`or every other day with a caliper, and the volumes were calculated by using the
`⫻ d2
`⫻ d3), where d1, d2, and d3 represent
`formula of an ellipsoid [V ⫽ ␲/6 (d1
`the three largest diameters]. Animals were also weighed the same day tumors
`253
`
`were measured. The animals were sacrificed when either their tumor burden
`exceeded 25,000 mm3 or when skin overlaying the tumor exhibited evidence
`of necrosis. All protocols involving animals were approved by the Veteri-
`na¨ramt of Baselstadt, Switzerland.
`Results are presented as mean ⫾ 1 SEM or as percentage of T/C (mean
`increase of tumor volumes of treated animals divided by the mean increase of
`tumor volumes of control animals multiplied by 100). The statistical signifi-
`cance of differences between treatment and control groups were determined by
`ANOVA followed by the Dunnett test. Statistical analyses on body weight
`were performed by ANOVA followed by Tukey’s test, and for comparison
`between weight at start and end of the experiment for individual animals, the
`paired t test was used. The level of significance was set at P ⬍ 0.05. Statistical
`calculations were performed using SigmaStat 2.03 (Jandel Scientific).
`Rat-Derived and Human Volunteer-Derived Tissue/PBMC Protein Ex-
`tract Preparation. CA20948 tumor-bearing rats were given 0.5, 1, 2, or 5
`mg/kg RAD001 or an equivalent volume of vehicle. At the indicated times
`after administration, rats were sacrificed, and tumor and shaved skin samples
`(for 0.5 and 5 mg/kg RAD001 doses) were dissected and weighed. Samples
`were rinsed in ice-cold PBS and immediately extracted in ice-cold extraction
`buffer [50 mM Tris-HCl (pH 8.0), 120 mM NaCl, 20 mM NaF, 1 mM EDTA, 6
`mM EGTA, 15 mM PPi, 30 mM p-nitrophenyl phosphate, 1 mM benzamidine,
`0.2 mM phenylmethylsulfonyl fluoride, and 0.1% NP40] with a constant ratio
`of 45 mg tumor/ml extraction buffer and 90 mg skin/ml extraction buffer, using
`a PT3000 Polytron (probe PT-DA 3012/2S; Kinematica AG) or a hand-held
`PT2100 Polytron (probe PT-DA 2112/2EC), respectively. Lysates were
`cleared by centrifugation for 30 min at 12,000 ⫻ g at 4°C. Supernatants were
`subsequently aliquoted, snap frozen on dry ice, and stored at – 80°C. In the
`case of skin samples, before further analysis, samples were centrifuged for 20
`min at 436,000 ⫻ g at 4°C to remove the fat fraction.
`Blood (for 0.5, 1, 2, and 5 mg/kg RAD001 doses) from tumor-bearing and
`non-tumor-bearing rats was withdrawn into syringes containing EDTA [0.5%
`(w/v) final] and then placed into an ice-cold tube and mixed. Unless otherwise
`stated, the blood from individual animals within the same treatment group was
`analyzed separately. The blood was immediately centrifuged for 20 min at
`430 ⫻ g at 4°C. The PBMCs, deposited at the interface between the RBCs and
`the plasma, were collected and pelleted by centrifugation for 5 min at 3000 ⫻ g
`at 4°C. PBMCs were washed with 10 ml of ice-cold PBS and then repelleted
`by centrifugation for 5 min at 3000 ⫻ g at 4°C. Cell pellets were resuspended
`in ice-cold extraction buffer containing 1% NP40 at the fixed ratio of 500 ␮l
`extraction buffer/10 ml initial blood volume. The cells were sheared by
`vigorous pipetting and then centrifuged for 30 min at 12,000 ⫻ g at 4°C.
`Supernatants were aliquoted, snap frozen on dry ice, and stored at ⫺80°C.
`Human blood from healthy volunteers was collected under medical super-
`vision into tubes containing either sodium citrate (BD Vacutainer 9NC; BD
`Vacutainer Systems, Plymouth, United Kingdom) or EDTA (BD Vacutainer
`K3E) as an anticoagulant. The blood was either immediately processed or, for
`ex vivo treatments, treated with 2, 20, and 200 nM RAD001 or DMSO vehicle
`for 30 min at room temperature. Human PBMCs were isolated and extracted
`as described for rat PBMCs.
`A549 Cell Culture and Protein Extract Preparation. A549 human lung
`carcinoma cells (CCL185) were obtained from the American Type Culture
`Collection (Manassas, VA) and cultured in RPMI 1640 medium (Amimed,
`Allschwil, Switzerland) supplemented with 10% FCS, 2 mM L-glutamine, and
`100 ␮g/ml penicillin/streptomycin at 37°C and 5% CO2. Cell lysates were
`prepared as described previously (48).
`Immunoblot Analysis. Cell lysates (30 – 40 ␮g) were electrophoretically
`resolved on denaturing SDS polyacrylamide gels (SDS-PAGE), transferred to
`polyvinylidene difluoride (Millipore Corp., Bedford, MA), and probed with the
`following primary antibodies: anti-S6 (provided by J. Mestan; Oncology
`Research, Novartis Pharma AG, Basel, Switzerland); anti-4E-BP1 (kindly
`provided by N. Sonenberg; McGill University, Montreal, Quebec, Canada);
`anti-eIF-4E (kindly provided by S. J. Morley; University of Sussex, Brighton,
`United Kingdom); anti-phospho-4E-BP1 Thr70, anti-S6K1, and anti-phos-
`pho-S6 Ser240/Ser244 (all from Cell Signaling Technology Inc., Beverly,
`MA); and anti-␤-tubulin (Tub2.1; Sigma, St. Louis, MO). “Decorated” pro-
`teins were revealed using horseradish peroxidase-conjugated antimouse or
`antirabbit immunoglobulins in conjunction with the enhanced chemilumines-
`cence procedure (Amersham Pharmacia Biotech Inc., Buckinghamshire,
`United Kingdom).
`
`Roxane Labs., Inc.
`Exhibit 1025
`Page 002
`
`

`
`RAPAMYCIN DERIVATIVE RAD001: EFFICACY AND BIOMARKERS
`
`Affinity Purification of 4E-BP1䡠eIF-4E Complexes with 7-Methyl-GTP-
`Sepharose. Rat tumor (1 mg), skin (0.7 mg), or PBMC (0.25 mg) extracts
`were diluted to a final volume of 500 ␮l in ice-cold extraction buffer and
`adjusted to a final NP40 concentration of 0.1%. The 4E-BP1䡠eIF-4E complexes
`were affinity purified with 20 ␮l of 7-methyl-GTP-Sepharose beads (Amer-
`sham Pharmacia Biotech Inc., Piscataway, NJ) by gentle rotation for 2.5 h at
`4°C. Proteins retained on the beads were washed twice with extraction buffer
`in the absence of NP40 and resuspended in 15 ␮l of Laemmli buffer. Dena-
`tured samples were subjected to 15% SDS-PAGE and transferred to polyvi-
`nylidene difluoride membranes. Membranes were first immunoblotted for
`4E-BP1 protein, followed by stripping as described previously (49) and re-
`probing for eIF-4E protein (see above).
`40S Ribosomal S6 Kinase Assay. Rat tumor (1 mg), skin (0.7 mg), or
`PBMC (0.25 mg) extracts were diluted to a final volume of 1 ml (tumor and
`skin) or 500 ␮l (PBMC) with ice-cold extraction buffer and adjusted to a final
`NP40 concentration of 1%. Human-derived PBMC extracts (0.8 –1 mg) were
`diluted to a final volume of 750 ␮l with ice-cold extraction buffer (final NP40
`concentration, 1%). In some experiments, human-derived PBMC extracts were
`first precleared with 20 ␮l of 50% protein A-Sepharose (Amersham Pharmacia
`Biotech, Uppsala, Sweden) by rotating for 20 min at 4°C. S6K1 was immu-
`noprecipitated from all extracts by addition of 2.5 ␮l of the M5 S6K1-specific
`polyclonal antibody and incubation on ice for 1 h, followed by retrieval of
`immunocomplexes with 20 ␮l of 50% protein A-Sepharose. S6K1 activity was
`measured using rat liver 40S ribosomal subunits as a specific substrate, as
`described previously (50), except that p-nitrophenyl phosphate was omitted in
`the reaction mixture. Phosphorylated S6 was resolved by 12.5% SDS-PAGE
`and analyzed using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA).
`[␥-32P]phosphate incorporation into S6 was quantified using ImageQuant
`(Molecular Dynamics). Where appropriate, the statistical significance of dif-
`ferences between treatment groups and untreated control groups was deter-
`mined using ANOVA or ANOVA on ranks followed by the Dunnett test. The
`level of significance was set at P ⬍ 0.05. Statistical calculations were per-
`formed using SigmaStat 2.03 (Jandel Scientific). Coefficient of variation is
`defined as SD divided by the mean and multiplied by 100.
`
`RESULTS
`
`Intermittent RAD001 Treatment Schedules Display Antitumor
`Efficacy. Short-term exposure to rapamycin in vitro has long-term
`antiproliferative effects on tumor cell
`lines (51), suggesting that
`intermittent treatment schedules may retain antitumor activity. Fur-
`thermore, daily oral administration of RAD001 is effective in rat
`models of autoimmune disease and allotransplantation (47, 52),
`whereas we have found that weekly (5 mg/kg) RAD001 dosing
`schedules have reduced immunosuppressive properties in rats as com-
`pared with daily treatment (2.5 mg/kg): 66 ⫾ 18% and 98 ⫾ 1%
`inhibition of IgG antibody response after dinitrophenol-coupled key-
`hole limpet hemocyanogen immunization, respectively.3 With these
`observations in mind, we evaluated whether RAD001 treatment
`schedules, with potentially reduced immunosuppressive properties,
`could elicit antitumor responses. Daily versus intermittent RAD001
`administration schedules were compared using the s.c. CA20948 rat
`pancreatic tumor model. Vehicle was used as a negative control, and
`the cytotoxic agent 5-FU was used as a positive control (Fig. 1; Table
`1, Experiment 1). RAD001 treatment at 0.5 or 2.5 mg/kg/day, six
`times a week, resulted in antitumor activity characterized by statisti-
`cally significant inhibition of tumor growth as compared with vehicle
`controls [treated tumor versus control tumor size (T/C), 30% and
`23%, respectively; P ⬍ 0.05 after 10 days of treatment; Fig. 1A; Table
`1, Experiment 1]. Statistically significant tumor growth suppression
`was also observed after intermittent administration of 5 mg/kg
`RAD001 twice a week (T/C, 36%) or once a week (T/C, 36%).
`Moreover, all RAD001 treatment schedules suppressed tumor growth
`to a similar extent as the cytotoxic 5-FU (T/C, 23%). Continued
`
`3 T. O’Reilly, H. A. Lane, and C. Heusser, unpublished data.
`
`Fig. 1. Suppression of tumor growth by daily and intermittent dosing schedules of
`RAD001. Tumors were established in male Lewis rats by s.c. injection of CA20948 tumor
`suspension obtained from donor rats. Treatments started on day 4 after inoculation.
`Formulated RAD001 was diluted in a 5% glucose solution and administered p.o. daily at
`a dose of 0.5 or 2.5 mg/kg (qd ⫻6, 6 times/week) or once (wk ⫻1) or twice (wk ⫻2)
`weekly at 5 mg/kg RAD001. Vehicle and 5-fluorouracil (5-FU ⫻4; 4 times/week) were
`administered as negative and positive controls, respectively. Tumor volumes were meas-
`ured (A), and rats were weighed (B) as described in “Materials and Methods.” Vehicle
`control-treated rats were sacrificed on day 10 due to tumor burden. Data are
`means ⫾ SEM (n ⫽ 7– 8 animals/group). Stars represent P ⬍ 0.05 versus vehicle controls.
`
`treatment with RAD001 after vehicle controls were sacrificed due to
`tumor burden led to a prolonged low tumor growth rate with all
`treatment schedules, resulting in similar tumor burden after 17 days of
`treatment as compared with 5-FU (Fig. 1A). For all treatment sched-
`ules, RAD001 was well tolerated, with no significant body weight loss
`or mortalities observed (Fig. 1B; Table 1, Experiment 1). These results
`demonstrate that RAD001 is a well-tolerated antitumor agent in a rat
`model of pancreatic cancer and indicate a potential for intermittent
`administration schedules that may allow dissociation of antitumor
`from immunosuppressive effects.
`RAD001 Modulates 4E-BP1 and S6K1 Activity in Tumor, Skin,
`and PBMCs Obtained from CA20948 Pancreatic Tumor-Bearing
`Rats. To investigate RAD001-specific effects on mTOR signaling in
`vivo, three CA20948 tumor-bearing rats were treated with vehicle or
`a single efficacious dose of RAD001 (5 mg/kg). Rats were sacrificed
`254
`
`Roxane Labs., Inc.
`Exhibit 1025
`Page 003
`
`

`
`RAPAMYCIN DERIVATIVE RAD001: EFFICACY AND BIOMARKERS
`
`Table 1 Effect of daily and intermittent RAD001 administration on CA20948 rat pancreatic tumor-bearing rats
`
`Tumor response
`
`Host response
`
`Schedule
`
`% T/Ca
`
`⌬ Tumor volume (mm3)
`
`⌬ Body weight (g)
`
`%⌬ Body weight
`
`Survival (alive/total)
`
`Compound
`
`Experiment 1
`Vehicle
`5-FU
`RAD001
`RAD001
`RAD001
`RAD001
`
`Experiment 2
`Vehicle
`RAD001
`RAD001
`RAD001
`
`2 ml/kg p.o. daily
`15 mg/kg i.v. 4⫻ weekly
`0.5 mg/kg p.o. daily
`2.5 mg/kg p.o. daily
`5 mg/kg p.o. weekly
`5 mg/kg p.o. twice weekly
`
`2 ml/kg p.o. daily
`0.5 mg/kg p.o. daily
`0.5 mg/kg p.o. weekly
`5 mg/kg p.o. weekly
`
`Experiment 3
`2 ml/kg p.o. weekly
`Vehicle
`0.5 mg/kg p.o. weekly
`RAD001
`1 mg/kg p.o. weekly
`RAD001
`2 mg/kg p.o. weekly
`RAD001
`3 mg/kg p.o. weekly
`RAD001
`5 mg/kg p.o. weekly
`RAD001
`a T/C, treated tumor versus control tumor size.
`b P ⬍ 0.05 versus control, Dunnett test.
`
`100
`23
`30
`23
`36
`36
`
`100
`23
`48
`14
`
`100
`48
`45
`32
`36
`24
`
`12972 ⫾ 2188
`2863 ⫾ 764b
`3904 ⫾ 856b
`2959 ⫾ 624b
`4652 ⫾ 1220b
`4604 ⫾ 928b
`
`12331 ⫾ 1410
`2894 ⫾ 567b
`5951 ⫾ 1739
`1708 ⫾ 339b
`
`19270 ⫾ 3918
`9275 ⫾ 1926
`8617 ⫾ 1704
`6161 ⫾ 1079b
`6869 ⫾ 611b
`4680 ⫾ 1593b
`
`12 ⫾ 8
`18 ⫾ 4
`35 ⫾ 7
`7 ⫾ 2
`22 ⫾ 5
`21 ⫾ 3
`
`29 ⫾ 2
`30 ⫾ 5
`36 ⫾ 2
`32 ⫾ 2
`
`28.3 ⫾ 2.1
`21 ⫾ 2.4
`32.8 ⫾ 2.7
`24.9 ⫾ 1.9
`24.3 ⫾ 3.3
`22.8 ⫾ 1.7
`
`5
`7
`14
`3
`8
`8
`
`14
`17
`15
`15
`
`10
`8
`12
`9
`9
`8
`
`8/8
`7/7
`7/7
`7/7
`7/7
`7/7
`
`8/8
`8/8
`8/8
`8/8
`
`8/8
`8/8
`8/8
`8/8
`6/6
`8/8
`
`matic dephosphorylation of its physiological substrate, 40S ribosomal
`protein S6, in tumor extracts (Fig. 2C). A similar reduction was not
`observed in skin and PBMC extracts because these tissues exhibited
`no detectable S6 phosphorylation in control animals. Interestingly, a
`
`24 h later, and protein extracts were prepared from tumors, skin, and
`PBMCs. By immunoblot analysis, mTOR could be detected in tumor
`and PBMC extracts; however, neither mTOR expression nor phos-
`phorylation on Ser2448 was modified on RAD001 treatment.4 In
`contrast, 4E-BP1 exhibited a decrease in Thr70 phosphorylation in
`tumor, skin, and PBMC extracts (Fig. 2A), a phenomenon associated
`with changes in 4E-BP1 electrophoretic mobility, particularly striking
`in PBMCs. This observation is consistent with previous work dem-
`onstrating dephosphorylation of 4E-BP1 on Thr70 in tumors derived
`from mouse xenograft models after five daily treatments with an ester
`of rapamycin CCI-779 (1 h after last administration; Ref. 53). Inter-
`estingly, the phosphorylation of another rapamycin-sensitive residue
`(Ser65; Refs. 5, 34, and 35) was unaffected by RAD001 treatment,4
`indicating that RAD001-insensitive phosphorylation of this site can
`occur as reported previously (54).
`To determine whether the decreased phosphorylation state of 4E-
`BP1 resulted in a change in functionality, the eIF-4E binding activity
`of 4E-BP1 was assessed using an in vitro 7-methyl-GTP-binding
`assay (Fig. 2B). Whereas similar levels of eIF-4E were recovered in
`the control- and RAD001-treated extracts, in two animals increased
`eIF-4E䡠4E-BP1 complex formation was clearly observed in skin and
`PBMC samples after RAD001 treatment. In tumor samples, two
`electrophoretically distinct forms of 4E-BP1 protein were bound to
`eIF-4E in vehicle control-treated rats (Fig. 2B). After RAD001 treat-
`ment, only the lower migrating form was found bound to eIF-4E, with
`an associated loss of the upper band consistent with reduced 4E-BP1
`phosphorylation levels (Fig. 2A). A similar 4E-BP1 doublet with
`eIF-4E binding activity has been observed previously in proliferating
`cells/tissue (29, 54) and presumably reflects differential 4E-BP1 phos-
`phorylation states within the proliferating tumor.
`To further assess the effect of RAD001 administration on the
`mTOR pathway, S6K1 protein and activity levels were also analyzed
`(Fig. 2, C and D). Whereas S6K1 protein levels were unaffected by
`RAD001 treatment (Fig. 2C), in vitro kinase assay using 40S riboso-
`mal subunits as a substrate revealed a statistically significant reduc-
`tion in S6K1 activity in all extracts [Fig. 2D; 83% (tumors), 80%
`(skin), and 75% (PBMC); all P ⬍ 0.05 versus vehicle-treated con-
`trols]. This reduction in S6K1 activity was associated with the dra-
`
`4 A. Boulay and H. A. Lane, unpublished data.
`
`Fig. 2. RAD001 administration inhibits mammalian target of rapamycin signaling in
`CA20948 tumor-bearing rats. S.c. CA20948 tumor-bearing rats received a single admin-
`istration of an efficacious dose of RAD001 (5 mg/kg) or vehicle and were sacrificed 24 h
`after administration (3 rats/group). Tumors, skin, and PBMCs were individually prepared
`and extracted as described in “Materials and Methods.” Results from individual rats are
`presented. A and C, total protein was subjected to electrophoresis followed by immunoblot
`analysis. Membranes were probed for eukaryotic initiation factor 4E-binding protein 1
`(4E-BP1) and phospho-threonine 70 4E-BP1 [P-4E-BP1 (Thr70)] levels, with eukaryotic
`initiation factor 4E (eIF-4E) and ␤-tubulin levels acting as loading controls (A) or
`ribosomal protein S6 kinase 1 protein, S6 40S ribosomal protein, and phospho-serine
`240/244 S6 [P-S6 (Ser240/Ser244)] levels (C). B, the level of 4E-BP1 bound to eIF-4E was
`measured by purification of 4E-BP1䡠eIF-4E complexes on 7-methyl-GTP-Sepharose, as
`described in “Materials and Methods,” followed by immunoblot analysis. D, ribosomal
`protein S6 kinase 1 was immunoprecipitated from equal amounts of total protein extract,
`and activity was measured by in vitro kinase assay using 40S ribosomal subunits as a
`specific substrate, as described in “Materials and Methods.” Phosphorimages (32P-S6) and
`PhosphorImager quantifications of the kinase assay are presented. Data are means ⫾ SD
`of n ⫽ 3 animals/group. Stars represent P ⬍ 0.05 versus vehicle-treated controls (Dunnett
`test).
`255
`
`Roxane Labs., Inc.
`Exhibit 1025
`Page 004
`
`

`
`RAPAMYCIN DERIVATIVE RAD001: EFFICACY AND BIOMARKERS
`
`reduction in S6 protein expression was observed in RAD001-treated
`skin, but not in tumor or PBMC extracts. A similar phenomenon has
`been reported previously in tumors after treatment of mice bearing
`human prostate cancer xenografts with CCI-779 (24). Moreover, the
`translation of S6 (as a 5⬘-terminal oligopyrimidine tract mRNA) has
`been shown to be specifically inhibited by rapamycin in 3T3 cells
`(36). It is not known why, in this model, RAD001 treatment only has
`effects on S6 expression in skin; however, differential downstream
`effects of mTOR pathway inhibition, depending on the tissue source,
`are a plausible possibility (54). Taken together, these data demonstrate
`that both 4E-BP1 and S6K1 pathways are affected in tumors, skin, and
`PBMC samples obtained from CA20948 tumor-bearing rats after a
`single administration of an efficacious dose of RAD001.
`Prolonged Inactivation of S6K1 in Tumors, Skin, and PBMCs
`Correlates with the Efficacy of Intermittent RAD001 Treatment
`Schedules. To investigate whether the antitumor efficacy of intermit-
`tent RAD001 treatment schedules is associated with prolonged effects
`on the mTOR pathway, CA20948 tumor-bearing rats were treated
`with a single dose of RAD001 (5 mg/kg) or vehicle, and tumor, skin,
`and PBMC extracts were prepared 12, 24, 48, or 72 h after adminis-
`tration. Because S6K1 was significantly inactivated 24 h after a single
`RAD001 administration in all tissues analyzed (Fig. 2D), long-term
`effects on mTOR function were assessed using the 40S kinase assay
`(Fig. 3). Tumor and skin extracts were obtained from each of 3
`rats/treatment group, whereas PBMC extracts were obtained from
`pooled blood from each treatment group. A dramatic reduction in
`S6K1 activity was already observed in tumors, skin, and PBMCs 12 h
`after RAD001 administration (91%, 91%, and 82% inhibition, respec-
`tively; all P ⬍ 0.05 versus untreated controls; Fig. 3). In contrast,
`treatment with vehicle did not significantly modulate S6K1 activity as
`compared with untreated controls (Fig. 3). Moreover, RAD001 treat-
`ment resulted in the sustained inactivation of S6K1 in all tissues. In
`tumors, statistically significant inhibition of S6K1 was maintained up
`to 48 h after administration, with some evidence of recovery after 72 h
`(80% and 62% inhibition at 48 and 72 h, respectively; Fig. 3A). In
`comparison, S6K1 derived from skin samples remained significantly
`inhibited for at least 72 h (72% inhibition at 72 h; Fig. 3B). Although
`a statistical analysis could not be performed on the pooled PBMC
`samples, S6K1 activity was also dramatically inhibited for up to 72 h
`in these samples (82% inhibition at 72 h; Fig. 3C). Thus, consistent
`with the antitumor efficacy of intermittent 5 mg/kg RAD001 treat-
`ment schedules in CA20948 tumor-bearing rats, a single administra-
`tion of 5 mg/kg RAD001 resulted in long-term inactivation of S6K1
`in tumors, skin, and PBMCs.
`The Antitumor Efficacy of Intermittent RAD001 Treatment
`Schedules Is Dose Dependent: Correlation Between Efficacy and
`Prolonged Effects on mTOR Effectors in Rat PBMCs. Following
`the observation that intermittent RAD001 (5 mg/kg) treatment sched-
`and 23%). Because both these schedules involve administration of 3
`ules significantly inhibited tumor growth, we explored the effect of
`mg/kg RAD001 per week, these data indicate that, with the same total
`RAD001 dose on the efficacy of weekly treatment schedules (Table 1,
`RAD001 exposure, intermittent dosing schedules can elicit equivalent
`Experiments 2 and 3). As expected, 5 mg/kg/week RAD001 signifi-
`antitumor responses as daily schedules.
`cantly suppressed CA20948 tumor growth as compared with vehicle
`controls (T/C, 14% and 24% at 7 a

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket